Phenome-transcriptome correlation unravels anxiety and depression related pathways.
The identification of pathways pertinent to human diseases is critical for gaining a better understanding of their pathophysiology. Pathway knowledge in turn can provide disease marker information required for diagnosis, drug development and improved patient treatment. Psychiatric disorders including anxiety and depression are complex diseases and are caused by a combination of multiple genetic and environmental factors affecting certain brain circuits. Here we used a systems biology approach to identify molecular pathways that affect anxiety- and depression-like phenotypes. For this purpose we screened pathways for stable enrichment in a great number of publicly available transcriptome data from the Gene Expression Omnibus related to anxiety- and depression-like phenotypes. In case of anxiety our analysis implicate a dysregulation of carbohydrate metabolism, tight junction and the phosphatidylinositol signaling system, whereas for depression gap junction, gonadotropin-releasing hormone signaling and ubiquitin-mediated proteolysis pathways are affected. Furthermore, both anxiety and depression show a dysregulation of VEGF signaling, long term potentiation and the glycolysis pathway. Molecular entities that are part of the identified pathways can serve as biomarkers and potential therapeutic targets for diagnosis and treatment of depression and anxiety disorders.
Max Planck Institute of Psychiatry, Proteomics and Biomarkers, 80804 Munich, Germany.
Philipp
P
Gormanns
Nikola S
NS
Mueller
Claudia
C
Ditzen
Simone
S
Wolf
Florian
F
Holsboer
Christoph W
CW
Turck
D000818:Animals; D001008:Anxiety Disorders / Q000235:genetics*; D001921:Brain / Q000378:metabolism; D003866:Depressive Disorder / Q000235:genetics*; D015870:Gene Expression / Q000235:genetics; D020869:Gene Expression Profiling; D006801:Humans; D051379:Mice; D010641:Phenotype; D051381:Rats